Daily cost of newer glaucoma agents

Journal of Ocular Pharmacology and Therapeutics

Volumn 15, Issue 5, 1999, Pages 379-388

  Stewart, William C ^a,b   Hudgins, Alison C ^a   Pruitt, Caroline A ^a   Sine, Cheryl ^a  

^a University of South Carolina   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; APRACLONIDINE; BRIMONIDINE; DORZOLAMIDE; EYE DROPS; LATANOPROST; NEW DRUG; TIMOLOL MALEATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG LABELING; FEMALE; GEL; HUMAN; INTRAOCULAR HYPERTENSION; MALE; OPEN ANGLE GLAUCOMA; TOPICAL DRUG ADMINISTRATION;

EID: 0032862779     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.1999.15.379     Document Type: Article

References (31)

1. Lederer Jr., C.M. and Harold, R.E. Drop size of commercial glaucoma medications. Am. J. Ophthalmol. 101:691-694, 1986.
2. Sorenson, S.J. and Abel, S.R. Drop size of ocular carteolol hydrochloride. Am. J. Hosp. Pharm. 51:1470-1473, 1994.
3. Ball, S.F. and Schneider, E. Cost of β-adrenergic receptor blocking agents for ocular hypertension. Arch. Ophthalmol. 10:654-657, 1992.
4. Hartenbaum, D., Stek, M., Haggert, B., et al. Quantitative and cost evaluation of three antiglaucoma beta-blocker agents: Timoptic-XE® versus two generic levobunolol products. Am. J. Man. Care 2:157-162, 1996.
5. Stewart, W.C., Sine, C., Cate, E., Minno, G.E., and Hunt, H.H. Daily cost of β-adrenergic blocker therapy. Arch. Ophthalmol. 115:853-856, 1997.
6. Stewart, W.C. Current and future glaucoma therapy. Ciba Clinical Symposium, 1997.
7. Neter, J., Wasserman, W., and Kutner, M.H. Analysis of covariance. Applied lineal statistical models. Richard D. Irvin, Inc., IL, 1985, p. 844-873.
8. Book, S.A. Essentials of Statistics. McGraw Hill Book Company, NY, 1978, p. 117-122, 205-215.
9. Stjernschantz, J. and Resul, B. Phenyl substituted prostaglandin analogs for glaucoma treatment. Drugs of the Future 17:691-704, 1992.
10. 2α-1-isopropylester in the cynomolgus monkey. Exp. Eye Res. 48:707-716, 1989.
11. 2α increases uveoscleral outflow in the cynomolgus monkey. Exp. Eye Res. 49:389-402, 1989.
12. 2α-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow. Am. J. Ophthalmol. 105:30-34, 1988.
13. 2α analog, on aqueous humor dynamics in human eyes. Ophthalmology 100:1297-1304, 1993.
14. Camras, C.B. and the United States Study Group. Comparison of latanoprost in patients with ocular hypertension and glaucoma. Ophthalmology 103:138-147, 1996.
15. Alm, A. and Stjernschantz, J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian latanoprost study group. Ophthalmology 102:1743-1752, 1995.
16. Watson, P.G., Stjernschantz, J., and the Latanoprost Study Group. A six-month, randomized double-masked study comparing latanoprost with timolol on open-angle glaucoma and ocular hypertension. Ophthalmology 103:126-137, 1996.
17. Johnstone, M. A. Brief latanoprost rx induces hypertrichosis. Invest. Ophthalmol. Vis. Sci. 39:S258, 1998.
18. Avakian, A., Renier, S.A., and Butler, DJ. Adverse effects of latanoprost on patients with medically resistant glaucoma. Report of four different cases. Arch. Ophthalmol. 116:679-680, 1998.
19. Warwar, R.E., Bullock, J.D., and Ballal, D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology 105:263-268, 1998.
20. Derick, R.J. Adrenergic agonist medications: basic mechanisms. J. Glaucoma 4(suppl):S1-S7, 1995.
21. Toris, C.B., Gleason, M.L., Camras, C.B., and Yablonski, M.E. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch. Ophthalmol. 113:1514-1517, 1995.
22. Derick, R.J., Walters, T.R., Robin, A.L., et al. Brimonidine tartrate: a one month dose response study. Invest. Ophthalmol. Vis. Sci. (suppl)34:1138, 1993.
23. Stewart, W.C. Prostaglandin analogues: their usage and benefits in glaucoma treatment. Ophthalmic Practice 14:48-55, 1996.
24. Stewart, W.C., Ritch, R., Shin, D.H., Lehmann, R.P., Shrader, C.E., and van Buskirk, E.M. The efficacy of apraclonidine as an adjunct to timolol therapy. Arch. Ophthalmol. 113:287-292, 1995.
25. Wang, R.F., Serle, J.B., Podos, S.M., and Sugrue, M.F. MK-507 (L-671, 152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys. Arch. Ophthalmol. 109:1297-1299, 1991.
26. Lippa, E.A., Carlson, L.E., Ehinger, B., et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch. Ophthalmol. 110:495-499, 1992.
27. Lippa, E.A., Schuman, J.S., Higginbotham, E.J., et al. MK-507 versus sezolamide: Comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology 98:308-313, 1991.
28. Wilkerson, M., Cyrlin, M., Lippa, E.A., et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch. Ophthalmol. 111:1343-1350, 1993.
29. Kitazawa, Y., Azuma, I., Iwata, K., et al. Dorzolamide, a topical carbonic anhydrase inhibitor: A two-week dose response study in patients with glaucoma or ocular hypertension. J. Glaucoma 3:275-279, 1994.
30. Strahlman, E., Tipping, R., Vogel, R., and the International Dorzolamide Study Group. A double masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch. Ophthalmol. 113:1009-1016, 1995.
31. Kass, M.A., Hodapp, E., Gordon, M., Kolker, A.E., and Goldberg, I. Patient administration of eyedrops: Observation. Part II. Ann. Ophthalmol. 14:889, 1982.